Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Farletuzumab ecteribulin by Eisai for Ovarian Cancer: Likelihood of Approval
Farletuzumab ecteribulin is under clinical development by Eisai and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...
Farletuzumab ecteribulin by Eisai for Fallopian Tube Cancer: Likelihood of Approval
Farletuzumab ecteribulin is under clinical development by Eisai and currently in Phase II for Fallopian Tube Cancer. According to GlobalData,...
Farletuzumab ecteribulin by Eisai for Peritoneal Cancer: Likelihood of Approval
Farletuzumab ecteribulin is under clinical development by Eisai and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase...
Farletuzumab ecteribulin by Eisai for Epithelial Ovarian Cancer: Likelihood of Approval
Farletuzumab ecteribulin is under clinical development by Eisai and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData,...